Jay Mohan, DO
Interventional Cardiology · Mount Clemens, MINPI 1366882656
Payments from drug & device makers
Across 601 payments — averaging $309.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inari Medical, Inc.$106K
- Shockwave Medical, Inc$34K
- Stryker$14K
- Medtronic$8K
- Abbott$5K
- Getinge USA Sales, LLC$5K
- plus $14K from 41 others
Across 1 payment — averaging $3750.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Inari Medical, Inc.$4K
What the payments were for
- Consulting fees$54,26530%
- Speaking & faculty fees$76,98643%
- Travel & lodging$22,24812%
- Food & beverage$24,36614%
- Education$4070%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CT THROMBECTOMY SYSTEM KIT$114,541
- FLOWTRIEVER CATHETER, S$95,428
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$32,147
- FlowTriever$5,248
- ClotTriever$5,146
- Indigo System$2,069
- CARDIOHELP$1,600
- Vasoview Hemopro 2$1,598
- CARDIOSAVE HYBRID, TYPE B PLUG$1,336
- OPTIS$1,291
- SYMPLICITY G3$652
- AVEIR$575
- Assure WCD$512
- Peripheral Orbital Atherectomy System$427
- WATCHMAN Access System$399
- ELUVIA$396
- CLOTTRIEVER BOLD CATHETER$239
- PASCAL$230
- AMPLATZER Occluders$199
- CAMZYOS$165
How this compares
$185,772 in reported general payments places this provider in the 80th percentile of 187 interventional cardiology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 345 | $388,153 |
| XareltoRivaroxaban | 67 | $83,713 |
| EntrestoSacubitril/Valsartan | 27 | $40,142 |
| Repatha SureclickEvolocumab | 39 | $32,918 |
| Repatha SyringeEvolocumab | 33 | $27,741 |
| FarxigaDapagliflozin Propanediol | 26 | $26,458 |
| JardianceEmpagliflozin | 17 | $22,787 |
| ClopidogrelClopidogrel Bisulfate | 323 | $6,333 |
| Metoprolol Succinate | 338 | $5,709 |
| Atorvastatin Calcium | 285 | $4,187 |
| Ranolazine ErRanolazine | 37 | $3,520 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 157 | $3,000 |
| Carvedilol | 193 | $2,900 |
| Rosuvastatin Calcium | 127 | $2,391 |
| Bumetanide | 41 | $2,139 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $142 | $388,153345 claims |
| Johnson & JohnsonXarelto | $327 | $83,71367 claims |
| NovartisEntresto | $376 | $40,14227 claims |
| AstraZenecaFarxiga | $169 | $26,45826 claims |
| Boehringer IngelheimJardiance | $175 | $22,78717 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 187 interventional cardiology providers in Michigan.
Other interventional cardiology in Mount Clemens
- Amir KakiDetroit$2.3M
- William MerhiGrand Rapids$2M
- Shukri DavidSouthfield$1.6M
- Qaiser ShafiqSouthgate$1.3M
- Marcel ZughaibSouthfield$1.2M
- Jason RicciPetoskey$1.1M
- Khaldoon AlaswadDetroit$1.1M
- Paul GrossmanAnn Arbor$1.1M
- Tamam MohamadDetroit$960K
- Harry ColferPetoskey$940K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.